Kathleen C. Munger
YOU?
Author Swipe
View article: Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics: Commentary
Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics: Commentary Open
View article: Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome with dimethyl fumarate therapy: The role of acute on chronic lymphopenia
Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome with dimethyl fumarate therapy: The role of acute on chronic lymphopenia Open
Progressive multifocal leukoencephalopathy (PML) is a rare complication associated with dimethyl fumarate (DMF) treatment for multiple sclerosis (MS). Chronic lymphopenia is considered a risk factor for DMF-associated PML. We report a 58 y…
View article: The impact of cognitive rehabilitation on quality of life in multiple sclerosis: A pilot study
The impact of cognitive rehabilitation on quality of life in multiple sclerosis: A pilot study Open
Background Cognitive impairment in people with multiple sclerosis (pwMS) negatively impacts daily function and quality of life (QoL). Prior studies of cognitive rehabilitation in pwMS have shown limited benefit but many focused on cognitiv…
View article: The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies Open
Alemtuzumab was designed to reduce the immunogenicity of the parent CD52-specific rat immunoglobulin. Although originally marketed for use in cancer (Mabcampath®), alemtuzumab is currently licensed and formulated for the treatment of relap…
View article: Difficult Discharges to Skilled Nursing Facilities Attributed to Multiple Sclerosis Medications: An Observational Study
Difficult Discharges to Skilled Nursing Facilities Attributed to Multiple Sclerosis Medications: An Observational Study Open
Background: The costs of multiple sclerosis (MS) disease-modifying therapies (DMTs) and certain symptomatic treatments (ie, dalfampridine [DFP]) are high. Consolidated billing models require that medication costs be covered by skilled nurs…